Literature DB >> 3435123

Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.

D J Hardy1, R N Swanson, D M Hensey, N R Ramer, R R Bower, C W Hanson, D T Chu, P B Fernandes.   

Abstract

The in vitro and in vivo properties of a new 1-difluorophenyl-6-fluoroquinolone, temafloxacin hydrochloride (A-62254), were compared with those of difloxacin and ciprofloxacin. Temafloxacin hydrochloride was as active as ciprofloxacin and difloxacin against staphylococci and as active as ciprofloxacin and 2 twofold dilutions more active than difloxacin against streptococci. Against gram-negative enteric bacteria and Pseudomonas aeruginosa, temafloxacin hydrochloride was 2 twofold dilutions more active than difloxacin but 2 to 4 twofold dilutions less active than ciprofloxacin. The MICs of temafloxacin hydrochloride and difloxacin were increased by 2 to 5 twofold dilutions in urine at pH 6.5 compared with 4 to 5 twofold-dilution increases in the MICs of ciprofloxacin. The MICs of temafloxacin hydrochloride, difloxacin, and ciprofloxacin were increased by 1 to 3 twofold dilutions in serum. The MICs of temafloxacin hydrochloride, difloxacin, and ciprofloxacin were the same or within 1 to 2 twofold dilutions at pHs 6.5, 7.2, and 8.0. When administered orally in mouse protection tests, temafloxacin hydrochloride was as active as difloxacin and 5 to 10 times more active than ciprofloxacin against infections with Staphylococcus aureus and streptococci. Against infections with gram-negative enteric bacteria and P. aeruginosa, temafloxacin hydrochloride was as active as difloxacin and ciprofloxacin. Temafloxacin hydrochloride was three times less active than difloxacin but was five times more active than ciprofloxacin against infections with Salmonella typhimurium. Temafloxacin hydrochloride was as active as difloxacin and ciprofloxacin against P. aeruginosa and Proteus mirabilis pyelonephritis in mice. The peak serum concentration and serum half-life of temafloxacin hydrochloride in mice were approximately one-half and one-sixth, respectively, that of difloxacin after oral administration. The peak serum concentration of temafloxacin hydrochloride in mice after oral administration was six times higher than that of ciprofloxacin, and the serum half-life was equal to that of ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3435123      PMCID: PMC175036          DOI: 10.1128/AAC.31.11.1768

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.

Authors:  J M Stamm; C W Hanson; D T Chu; R Bailer; C Vojtko; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

2.  Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.

Authors:  A L Barry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

3.  Frequency of appearance of resistant variants to norfloxacin and nalidixic acid.

Authors:  G J Duckworth; J D Williams
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

4.  The frequency of in-vitro resistance development to fluoroquinolones and the use of a murine pyelonephritis model to demonstrate selection of resistance in vivo.

Authors:  P B Fernandes; C W Hanson; J M Stamm; C Vojtko; N L Shipkowitz; E St Martin
Journal:  J Antimicrob Chemother       Date:  1987-04       Impact factor: 5.790

5.  In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.

Authors:  P B Fernandes; D T Chu; R R Bower; K P Jarvis; N R Ramer; N Shipkowitz
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

6.  The in vitro and in vivo activity of ciprofloxacin.

Authors:  H J Zeiler; K Grohe
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

7.  Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

Authors:  C C Sanders; W E Sanders; R V Goering; V Werner
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

8.  Difloxacin metabolism and pharmacokinetics in humans after single oral doses.

Authors:  G R Granneman; K M Snyder; V S Shu
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

9.  In vitro activity of ciprofloxacin (Bay o 9867).

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

10.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

View more
  53 in total

1.  Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium.

Authors:  M E Erwin; R N Jones
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

2.  Disk diffusion quality control guidelines for Haemophilus susceptibility tests using cefdinir, CI-960, fleroxacin, temafloxacin, and trospectomycin.

Authors:  M J Bale; R N Jones; M E Erwin; F P Koontz; E H Gerlach; P R Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

3.  The relative bioavailability of temafloxacin administered through a nasogastric tube with and without enteral feeding.

Authors:  T J Lubowski; C H Nightingale; K Sweeney; R Quintiliani
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

4.  Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and temafloxacin.

Authors:  A L Barry; M A Pfaller; P C Fuchs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-03       Impact factor: 3.267

5.  Effects of 2 quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics.

Authors:  F Sörgel; G Mahr; G R Granneman; U Stephan; P Nickel; P Muth
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

Review 6.  Structure-activity relationships of the fluoroquinolones.

Authors:  D T Chu; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

7.  In vitro activity of sparfloxacin.

Authors:  N X Chin; J W Gu; K W Yu; Y X Zhang; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

8.  Activity of temafloxacin against respiratory pathogens.

Authors:  R N Swanson; D J Hardy; D T Chu; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

9.  Pharmacokinetics of temafloxacin in humans after single oral doses.

Authors:  G R Granneman; P Carpentier; P J Morrison; A G Pernet
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

10.  Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent.

Authors:  D Gargallo-Viola; M Esteve; M Moros; R Coll; M A Xicota; C de Andres; R Roser; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.